13D Filing: Ardsley Partners and Marrone Bio Innovations Inc (MBII)

Page 1 of 15

Marrone Bio Innovations Inc (NASDAQ:MBII): Philip Hempleman’s Ardsley Partners filed an amended 13D.

You can check out Ardsley Partners’ latest holdings and filings here.

Please follow Ardsley Partners (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Ardsley Partners or update its stock holdings.

Follow Philip Hempleman's Ardsley Partners

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Ardsley Advisory Partners 0 15,681,580 0 15,681,580 15,681,580 14.61%
Philip J. Hempleman 0 15,681,580 0 15,681,580 15,681,580 14.61%
Ardsley Partners I 0 15,631,580 0 15,631,580 15,631,580 14.56%
Ardsley Partners Fund II 0 595,300 0 595,300 595,300 0.58%
Ardsley Partners Advanced Healthcare Fund 0 1,189,700 0 1,189,700 1,189,700 1.17%
Ardsley Partners Renewable Energy Fund 0 13,846,580 0 13,846,580 13,846,580 12.90%
Ardsley Duckdive Fund 0 50,000 0 50,000 50,000 0.05%

Follow Philip Hempleman's Ardsley Partners

Page 1 of 15 – SEC Filing


DC 20549




to be included in statements filed pursuant

to rules 13d-1(a) and amendments thereto

pursuant to rule 13d-2(a)1

Bio Innovations, Inc.

of Issuer)


of Class of Securities)



Napoli c/o Ardsley Advisory Partners

Harbor Drive, 4th Floor

Connecticut 06902

Address and Telephone Number of Person Authorized to Receive Notice and Communications)

5, 2018

of Event Which Requires Filing of this Statement)

the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this
Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. x


Note: Schedules
filed in paper format shall include a signed original and five copies of the Schedule, including all exhibits. See Rule
13d-7(b) for other parties to whom copies are to be sent.

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect
to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures
provided in a prior cover page.


information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).

Follow Marrone Bio Innovations Inc (NASDAQ:MBII)

Page 1 of 15